Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02158858
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:12.613943+00:00
Published At
2025-10-08T00:00:00+00:00
Record Updated At
2025-10-08
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Myelofibrosis", "Leukemia, Myelocytic, Acute", "Myelodysplastic/Myeloproliferative Neoplasm", "Myelodysplastic Syndrome (MDS)", "Preleukemia", "Primary Myelofibrosis", "Myeloproliferative Disorders", "Bone Marrow Disease", "Hematological Disease", "Precancerous Conditions", "Neoplasms", "Leukemia", "Neoplasms by Histologic Type", "Essential Thrombocytosis"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-10-08"
protocolSection.identificationModule.nctId
"NCT02158858"
protocolSection.identificationModule.officialTitle
"A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Myelofibrosis (protocolSection.conditionsModule.conditions)
  • Leukemia, Myelocytic, Acute (protocolSection.conditionsModule.conditions)
  • Myelodysplastic/Myeloproliferative Neoplasm (protocolSection.conditionsModule.conditions)
  • Myelodysplastic Syndrome (MDS) (protocolSection.conditionsModule.conditions)
  • Preleukemia (protocolSection.conditionsModule.conditions)
  • Primary Myelofibrosis (protocolSection.conditionsModule.conditions)
  • Myeloproliferative Disorders (protocolSection.conditionsModule.conditions)
  • Bone Marrow Disease (protocolSection.conditionsModule.conditions)
  • Hematological Disease (protocolSection.conditionsModule.conditions)
  • Precancerous Conditions (protocolSection.conditionsModule.conditions)
  • Neoplasms (protocolSection.conditionsModule.conditions)
  • Leukemia (protocolSection.conditionsModule.conditions)
  • Neoplasms by Histologic Type (protocolSection.conditionsModule.conditions)
  • Essential Thrombocytosis (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.